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reduce the stroke rate.
METHODS 133 patients underwent TAVR procedures using the Claret
Cerebral Protection System (CPS; Claret Medical, Inc., Santa Rosa, CA)
to guard against peri-procedural strokes. Various TAVR prostheses
were used (55 Sapien 3, 36 Sapien/Sapient XT, 28 Corevalve/Evolut R,
8 Portico, 4 JenaValves, 1 Centera, 1 Direct Flow) as well as different
access routes (transfemoral 119, transapical 8, transaxillary 6). In 21
cases, valve-in-valve procedures were performed in degenerated
surgical aortic bioprostheses; 9 patients had a left atrial appendix
(LAA) thrombus. Mean patient age was 80  8 years; mean logistic
EuroSCORE of 27  18%. Clinical follow-up was obtained at 3 days
after the intervention and at discharge (mean 10 days). Histological
analyses were performed in 52 patients by the CVPath Institute in
Gaithersburg, MD (42 additional analyses are still in progress).
RESULTS Stroke rate after TAVR was 2.3% (3/133) at 3 days post TAVR;
all were major strokes. Sapien 3 (n¼2) and Evolut R (n¼1) prostheses
had been used in these patients. In 2 patients the cerebral protection
device was not positioned as intended (one malpositioning, one posi-
tioning not possible due to kinking of the truncus brachiocephalicus)
and in 1 patient the device dislocated during peri-procedural resusci-
tation and additional deﬁbrillation in the presence of LAA thrombus.
Histological investigations showed debris in the ﬁlters in 96% of cases.
Debris was more common in the distal (87%) than in the proximal ﬁlter
(73%). Acute thrombus was the most common type of debris found in
56% of ﬁlters. In 30% of all cases, valve and arterial wall tissue and
calciﬁcation was found. Organized thrombus was found in 12%, while
foreign material was found in 7% of all cases. The percentages of
different types of debris were similar in proximal and distal ﬁlters.
Foreign material was captured in 13% and 17% (proximal/distal) of ﬁl-
ters but was not present when using the Sapien 3 prosthesis.
CONCLUSIONS Feasibility and safety of the Claret CPS was docu-
mented in these 133 patients. Histopathological analyses showed high
overall debris capture and retrieval rates, with prevalence of thrombus
over valve and arterial wall tissue, calciﬁcation and foreign material.
Sapien 3 implantations showed no foreign material in the ﬁlters. Pro-
cedural stroke rate was low at 2.3%, occurring only when the cerebral
protection device was not properly placed. Stroke rate for optimally
positioned devices was 0% in this registry, which included also patients
with LAA thrombus and cardiogenic shocks. Further experience and
investigation is needed to ensure optimal positioning, to quantify any
reduction in new cerebral lesions using protection, and to deﬁne which
patients are at the higher risk for cerebral embolization.
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BACKGROUND Transcatheter aortic valve-in-valve (ViV) implantation
into degenerated bioprostheses has become an alternative toreoperative aortic valve replacement. Remaining challenges relate to
residual stenosis after implantation. We report on the ﬁrst compre-
hensive analysis of clinical outcomes of SAPIEN 3 (S3) used for ViV
and compare to early generation SAPIEN XT (SXT) balloon-expandable
device.
METHODS A total of 404 ViV procedures using SXT or S3 balloon
expandable devices from the Valve-in-Valve International Data
(VIVID) registry were included. Groups were matched for baseline
characteristics and surgical bioprosthesis size and type. Subsequently,
a group of 48 patients that underwent S3 implantation was compared
to a 2:1 matched group of 96 patients that underwent SXT implanta-
tion. Procedural and clinical outcomes were deﬁned by Valve Aca-
demic Research Consortium II (VARC-II).
RESULTS Patients included in the matched groups had an average age
of 75.611.1yrs and 56.9% were male. Failure mode was stenosis,
regurgitation and the combination of both in 35.4%, 33.3% and 29.3%,
respectively. Mean STS PROM was 97.4%. Average bioprostheses
label size was similar between the groups: 23.71.8 mm (S3) vs.
242.1 mm (SXT), p¼0.44. Small surgical valves (label size21mm)
were apparent in 18.8% of S3 vs. 19.2% of SXT cases (p¼0.88). Pro-
cedures were performed using transfemoral access in 87.5% (S3) vs.
80.2% of (SXT, p¼0.28). Implanted transcatheter valve sizes were
23.61.3 mm (S3) vs. 24.61.9 mm (SXT, p¼0.001). There was a trend
towards lower 30-day mortality in the S3 group (0% vs. SXT 7%, p ¼
0.08). Rates of adverse events were low: coronary obstruction in 0%
(S3) vs. 1.1% (SXT, p ¼ 0.48), major stroke in 0% (S3) vs. 1.1% (SXT, p ¼
0.48). In patients without a permanent pacemaker at baseline, a trend
towards higher rates of pacemaker implantation was observed after S3
ViV (8.3% vs. SXT 2.1%, p¼0.08). Residual aortic regurgitation of
more than mild degree was noticed in 2.1% (S3) vs. 9.5% (SXT, p¼0.1)
of patients. Mean gradients after implantation were similar:
18.18.4 mm (S3) vs. 17.69.2 mm (SXT, p¼0.76), as was the rate of
elevated post procedural gradients: 20mmHg 38.3% (S3) vs. 34.8%
(SXT, p¼0.69), 40mmHg 4.3% (S3) vs. 6.7% (SXT, p¼0.56). The
incidence of severe patient-prosthesis mismatch (32.4% [S3] vs. 28.1%
[SXT], p¼0.67) was similar but a trend towards greater effective oriﬁce
areas was observed after SXT implantation (1.40.4 mm [S3] vs.
1.50.5 mm [SXT], p¼0.1).
CONCLUSIONS In this multicenter experience, excellent clinical
outcomes with low complication rates were achieved after aortic ViV
implantation with the S3 transcatheter heart valve. However, post-
procedural gradients remained elevated with this second generation
device and similar to early generation device, underlining the need for
careful patient selection in order to avoid severe patient-prosthesis
mismatch after ViV implantation.
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BACKGROUND Oral antiplatelet medications are routinely adminis-
tered to patients following TAVR, however, there are limited data on
the ideal antithrombotic treatment strategy or the patterns of medi-
cation use and outcomes in the U.S.
METHODS Using the STS/ACC TVT Registry we evaluated patients
without pre-operative atrial ﬁbrillation undergoing TAVR from 2011 to
2014. Clinical outcomes included death, bleeding, and stroke at 1 year
of follow up.
RESULTS Overall, 5,974 patients treated at 298 hospitals were
analyzed. Of these, 69% (n¼4,132) were discharged on combined
aspirin and a clopidogrel (DAPT), 28% (n¼1,344) on aspirin alone,
5%(n¼294) on clopidogrel alone, and 3% (n¼ 204) on no antiplatelet
therapy. Antiplatelet prescribing patterns varied signiﬁcantly at the
hospital level (Figure). Patients discharged on DAPT were similar with
respect to age (84 vs 84 years), gender (51.6% vs. 53.1% female), and
most comorbid illnesses, but had higher rates of CAD (67.1% vs.
55.7%), and lower STS PROM risk scores (6.1 vs. 6.4). Regarding
clinical outcomes, unadjusted 1 year death (13.3% vs. 16.5%;
p<0.001) and bleeding rates (15.4% vs. 19.6%; p¼0.001) were lower
in patients prescribed DAPT after TAVR, while stroke rates were not
B48 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5signiﬁcantly different (3.4% vs. 4.3%; p¼0.07) compared with those
not prescribed DAPT.
CONCLUSIONS While the majority of TAVR patients in the U.S.
receive DAPT therapy at hospital discharge, antiplatelet prescribing
patterns varied signiﬁcantly among US TAVR hospitals. Outcomes for
DAPT treated patients were generally better than those not treated
with DAPT, but further studies are needed to deﬁne the best antith-
rombotic medical treatment following TAVR.
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BACKGROUND Transcatheter aortic valve replacement (TAVR) has
been established as alternative treatment for inoperable or high-risk
patients with symptomatic severe aortic stenosis. However, TAVR for
bicuspid aortic valve stenosis has been still relatively contraindicated
and the clinical data of TAVR for bicuspid aortic valve has been
limited. We sought to evaluate the clinical outcomes of TAVR for
bicuspid aortic valve.
METHODS The Bicuspid TAVR registry was conducted in 9 centers
from 7 countries in Asia, Europe and North America between March
2006 and February 2015. Baseline demographics, procedural and
echocardiographic data were prospectively collected from each center
and a joint database was created.
RESULTS One hundred and thirty-one patients were included. Mean
age was 77.2  9.4 years and 33.6% were female. Medtronic CoreValve,
Edwards SAPIEN/XT and SAPIEN 3 were used in 48.9%, 43.5% and
5.3% of patients, respectively. Approaches were either transarterial
(transfemoral, 78.6%; subclavian, 1.5%; direct aortic, 13.0%) or trans-
apical (6.1%). Mean logistic European System for Cardiac Operative
Risk Evaluation (EuroSCORE) and Society of Thoracic Surgeons (STS)
score were 16.2  12.5 and 5.3  5.1, respectively. At 30 days, the
incidence of all stroke, major vascular complications, life-threateningbleeding, and acute kidney injury (stage 2 or 3) were 1.6%, 4.6%, 4.6%
and 3.8%, respectively. Paravalvular regurgitation moderate or
greater occurred 6.3% in overall, 8.6% in CoreValve, 4.3% in SAPIEN/
XT and 0.0% in SAPIEN 3. Rates of death at 30 days and 1 year were
4.1% and 12.7% for overall, 7.0% and 16.6% for SAPIEN/XT, and 1.6%
and 10.1% for CoreValve, respectively. In multivariate analysis, age
(hazard ratio, 1.17; 95% conﬁdence interval: 1.01 – 1.35; p ¼ 0.038) and
creatinine (hazard ratio, 1.74; 95% conﬁdence interval: 1.05 – 2.89;
p ¼ 0.03) were independent predictors of all-cause death.
Clinical Outcomes of TAVR for Bicuspid Aortic Valve StenosisOverall
(N [ 121)SAPIEN/XT
(N [ 57)CoreValve
(N [ 64) p valueMortality at 30
days5 (4.1%) 4 (7.0%) 1 (1.6%) 0.19Mortality at 1
year14 (12.7%) 8 (16.6%) 6 (10.1%) 0.31All stroke 2 (1.7%) 1 (1.8%) 1 (1.6%) 0.99Life-threatening
bleeding6 (5.0%) 2 (3.5%) 4 (6.3%) 0.68Acute kidney
injury stage 2
to 35 (4.1%) 4 (7.0%) 1 (1.6%) 0.19Major vascular
complication5 (4.1%) 5 (8.8%) 0 (0.0%) 0.02Aortic
regurgitation
moderate or
greater7 (6.7%) 2 (4.3%) 5 (8.6%) 0.08Device success 111 (91.7%) 53 (93.0%) 58 (90.6%) 0.75Safety endpoint
at 30 days98 (81.0%) 42 (73.7%) 56 (87.5%) 0.065CONCLUSIONS This registry reﬂects the real-life experience of TAVR
for bicuspid aortic valve stenosis.
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BACKGROUND Experience with transcatheter aortic valve implanta-
tion (TAVI) for severe aortic regurgitation is limited due to the risk of
insufﬁcient anchoring of the valve stent within the non-calciﬁed
aortic annulus. The aim of this study is to report the initial experience
